drugset / Trial / NCT02318914
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
NaSingle-groupOpen-labelTreatment
Summary
The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers
Timeline
- Start
- 2014-11
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gevokizumab | Monoclonal antibody | — | Subcutaneous |